Front Desk: 469-391-0070
Bortezomib Treatment: Uses, Dosage & Side Effects Explained
Summary of Key Points
Bortezomib is a prescription medication commonly used to treat specific types of cancer, including multiple myeloma and lymphoma. As a proteasome inhibitor, it works by interfering with the growth of cancer cells, ultimately causing their destruction. This medication is administered via injection and is typically given in treatment cycles. Common side effects may include fatigue, nausea, and reduced blood cell counts. It is crucial to consult your healthcare provider before starting or adjusting your treatment plan to ensure it is safe and effective for your condition.
Names of the Medication
US Brand Name: Velcade
Generic Name: Bortezomib
The generic name, Bortezomib, identifies the active ingredient in the medication, while Velcade is the brand name under which it is marketed. Both terms are frequently used when discussing treatment options involving this drug.
Pharmacologic Category
Bortezomib belongs to a class of drugs known as proteasome inhibitors. These medications are specifically designed to disrupt certain cellular processes in cancer cells, making them an effective tool in cancer treatment.
Bortezomib Dosage and Administration
The dosage, frequency, and duration of Bortezomib treatment depend on the specific condition being treated. It is essential to follow your healthcare provider’s instructions carefully and consult them before making any changes to your prescribed regimen. For personalized guidance, consider scheduling a consultation with a qualified medical professional, either in person or via telemedicine.
Bortezomib for Multiple Myeloma
For patients with multiple myeloma, Bortezomib is typically administered as an injection at a dose of 1.3 mg/m². The treatment is given twice a week for two weeks, followed by a 10-day rest period. This cycle is repeated every 21 days.
Bortezomib for Waldenström’s Macroglobulinemia
In the treatment of Waldenström’s macroglobulinemia, Bortezomib is administered at a dose of 1.3 mg/m² via injection. The schedule involves two doses per week for two weeks, followed by a 10-day rest period, with the cycle repeating every 21 days.
Bortezomib for Mantle Cell Lymphoma
For mantle cell lymphoma, the standard dose of Bortezomib is 1.3 mg/m². It is administered twice weekly for two weeks, followed by a 10-day rest period, with the cycle repeating every 21 days.
Bortezomib for Amyloidosis
In cases of amyloidosis, Bortezomib is given at a dose of 1.3 mg/m². The treatment schedule involves two injections per week for two weeks, followed by a 10-day rest period, with the cycle repeating every 21 days.
Bortezomib for Non-Hodgkin Lymphoma
For non-Hodgkin lymphoma, Bortezomib is typically administered at a dose of 1.3 mg/m². The treatment is given twice weekly for two weeks, followed by a 10-day rest period, with the cycle repeating every 21 days.
Bortezomib for Acute Myeloid Leukemia
In the treatment of acute myeloid leukemia, Bortezomib is administered at a dose of 1.3 mg/m². The schedule consists of two injections per week for two weeks, followed by a 10-day rest period, with the cycle repeating every 21 days.
Bortezomib for Chronic Lymphocytic Leukemia
For chronic lymphocytic leukemia, the standard dose of Bortezomib is 1.3 mg/m². It is administered twice weekly for two weeks, followed by a 10-day rest period, with the cycle repeating every 21 days.
Bortezomib for Peripheral T-cell Lymphoma
In cases of peripheral T-cell lymphoma, Bortezomib is administered at a dose of 1.3 mg/m². The treatment involves two injections per week for two weeks, followed by a 10-day rest period, with the cycle repeating every 21 days.
Bortezomib for Hodgkin Lymphoma
For Hodgkin lymphoma, the standard dose of Bortezomib is 1.3 mg/m². It is administered twice weekly for two weeks, followed by a 10-day rest period, with the cycle repeating every 21 days.
Bortezomib for Plasmacytoma
In the treatment of plasmacytoma, Bortezomib is administered at a dose of 1.3 mg/m². The schedule involves two injections per week for two weeks, followed by a 10-day rest period, with the cycle repeating every 21 days.
Dosage Forms and Strengths
Bortezomib is available as an injectable medication in the form of a powder for solution. Each vial contains a strength of 3.5 mg.
Administration Instructions for Bortezomib Treatment
Bortezomib, a commonly prescribed cancer medication, is administered through injection either under the skin (*subcutaneous*) or directly into a vein (*intravenous*). This treatment is typically provided by a healthcare professional in a clinical or hospital setting. Bortezomib is given on a cycle-based schedule, which includes treatment days followed by rest periods to allow your body time to recover. It is crucial to follow the schedule outlined by your healthcare provider. If you miss a dose, contact your provider promptly to determine the best course of action.
Contraindications for Bortezomib
Contraindications refer to specific conditions or situations where using a particular medication could be harmful. Before starting Bortezomib, it is essential to identify any contraindications that could affect your safety.
Who Should Not Take Bortezomib?
Allergy to Bortezomib or its components: Individuals with a known allergy to Bortezomib (commonly marketed as Velcade) or any of its ingredients should avoid this medication, as it can cause severe allergic reactions. Symptoms of an allergic reaction may include rash, swelling, or difficulty breathing.
Severe liver disease: Because Bortezomib is metabolized by the liver, patients with severe liver disease may be at higher risk of experiencing increased side effects or toxicity due to impaired drug processing.
Peripheral neuropathy: Bortezomib can exacerbate nerve damage (*neuropathy*). If you already have moderate to severe peripheral neuropathy, this medication may worsen symptoms such as pain, numbness, or weakness in your hands and feet.
Heart conditions: Patients with heart problems, including congestive heart failure or arrhythmias, may face heightened risks when taking Bortezomib. The medication can impact heart function and potentially worsen these conditions.
Drug-to-Drug Interactions with Bortezomib
Bortezomib may interact with other medications, which can either increase the likelihood of side effects or reduce the effectiveness of your treatment. It is important to inform your healthcare provider about all medications you are currently taking, including over-the-counter drugs and dietary supplements, before beginning Bortezomib therapy.
Common Medications That Interact with Bortezomib
Ketoconazole (Nizoral): This antifungal medication can increase Bortezomib levels in the body, raising the risk of side effects.
Rifampin (Rifadin): This antibiotic may decrease the effectiveness of Bortezomib by lowering its concentration in the bloodstream.
Phenytoin (Dilantin): This anti-seizure medication can reduce Bortezomib’s efficacy by accelerating its breakdown in the body.
Amiodarone (Pacerone): This heart medication may increase the risk of side effects, particularly those affecting heart function, when used alongside Bortezomib.
Bortezomib and Pregnancy
Is Bortezomib Safe During Pregnancy?
No, Bortezomib is not considered safe for use during pregnancy. This medication can harm a developing fetus, potentially leading to birth defects or pregnancy loss. If you are pregnant or planning to become pregnant, it is essential to discuss alternative treatment options with your healthcare provider. Should you become pregnant while undergoing Bortezomib therapy, contact your provider immediately to determine the appropriate next steps.
Bortezomib While Breastfeeding
Can You Take Bortezomib While Breastfeeding?
Breastfeeding while taking Bortezomib is not recommended. Although there is limited information on whether Bortezomib passes into breast milk, the potential for serious side effects in a nursing infant makes breastfeeding unsafe during treatment. If you are breastfeeding, consult your healthcare provider to explore alternative feeding options while undergoing Bortezomib therapy.
Estimated Cost of Bortezomib Treatment
The cost of Bortezomib can vary significantly depending on your location and the pharmacy you use. Without insurance, a 30-day supply of Bortezomib typically costs between $5,000 and $10,000 when using a GoodRx coupon. Prices may fluctuate, so it’s a good idea to check with your pharmacy or explore prescription discount services to find the most affordable option.
Possible Alternatives to Bortezomib
If Bortezomib is not the right fit for your treatment plan, there are other options available. It’s essential to consult your healthcare provider before making any changes to your prescribed regimen. You can also schedule a telemedicine appointment with one of our providers to discuss alternative treatments tailored to your specific condition.
Bortezomib Alternatives for Multiple Myeloma
Alternative Medications: Lenalidomide (Revlimid), Thalidomide (Thalomid), Carfilzomib (Kyprolis).
Lifestyle Changes: Incorporating a nutrient-rich diet, engaging in regular physical activity, and practicing stress management techniques can support your overall well-being and complement your treatment plan.
Bortezomib Alternatives for Waldenström’s Macroglobulinemia
Alternative Medications: Rituximab (Rituxan), Ibrutinib (Imbruvica).
Lifestyle Changes: Maintaining a balanced diet, staying physically active, and taking steps to prevent infections can help manage symptoms and improve quality of life.
Bortezomib Alternatives for Mantle Cell Lymphoma
Alternative Medications: Ibrutinib (Imbruvica), Acalabrutinib (Calquence).
Lifestyle Changes: Staying active and following a nutritious diet may enhance your overall health and quality of life during treatment.
Bortezomib Alternatives for Amyloidosis
Alternative Medications: Daratumumab (Darzalex), Cyclophosphamide (Cytoxan).
Lifestyle Changes: Reducing salt intake and carefully managing fluid levels can help alleviate symptoms related to organ involvement and improve comfort.
Bortezomib Alternatives for Non-Hodgkin Lymphoma
Alternative Medications: Rituximab (Rituxan), Obinutuzumab (Gazyva).
Lifestyle Changes: A well-balanced diet and regular exercise can strengthen your immune system and support overall health.
Bortezomib Alternatives for Acute Myeloid Leukemia
Alternative Medications: Cytarabine (Cytosar-U), Daunorubicin (Cerubidine).
Lifestyle Changes: Avoiding infections and maintaining proper nutrition are critical components of managing your health during treatment.
Bortezomib Alternatives for Chronic Lymphocytic Leukemia
Alternative Medications: Ibrutinib (Imbruvica), Venetoclax (Venclexta).
Lifestyle Changes: Engaging in regular exercise and following a balanced diet can help boost energy levels and overall well-being.
Bortezomib Alternatives for Peripheral T-cell Lymphoma
Alternative Medications: Romidepsin (Istodax), Brentuximab vedotin (Adcetris).
Lifestyle Changes: Staying physically active and maintaining a healthy diet can help manage symptoms and improve your quality of life.
Bortezomib Alternatives for Hodgkin Lymphoma
Alternative Medications: Brentuximab vedotin (Adcetris), Nivolumab (Opdivo).
Lifestyle Changes: Incorporating regular physical activity and a nutritious diet can support your treatment and overall health.
Bortezomib Alternatives for Plasmacytoma
Alternative Medications: Radiation therapy, Lenalidomide (Revlimid).
Lifestyle Changes: Managing stress and adopting a healthy lifestyle can enhance your overall well-being and complement your treatment plan.
Recent Updates on Bortezomib Research
Ongoing research is focused on improving the effectiveness of Bortezomib by combining it with newer immunotherapies and targeted treatments for multiple myeloma and other blood cancers. These advancements aim to enhance patient outcomes by reducing side effects and increasing survival rates. Additionally, researchers are exploring the potential benefits of using Bortezomib in earlier stages of treatment to slow disease progression. If you’re interested in learning more about emerging therapies or clinical trials, consider scheduling a telemedicine appointment with one of our healthcare providers for personalized guidance.
